Biotech Stocks At 52-Week Highs- CDNA, IART, AGL, BVS, ELVN
Biotech stocks hit 52-week highs on July 16, 2026 ahead of quarterly reports or a conference. CareDx (CDNA) rose to a 52-week high of $40.38% and reported Q1 revenue of $118M. Integra LifeSciences (IART) reached $20.26, with Q1 revenue $391.9M. Bioventus (BVS) hit $12.53, Q1 revenue $132M. Enliven Therapeutics (ELVN) hit $53.89 after a ~$460M public offering.
How this was made
The 30-second read
Why it matters
It provides company-specific updates for five biotech names, including Medicare coverage (CDNA), product and revenue outlook (IART, BVS), a 2026 revenue estimate (AGL), and a public offering plus clinical timeline (ELVN).
Market read
Traders can use the disclosed reimbursement update, financial ranges, and capital raise details to frame near-term catalyst expectations and risk (especially dilution).
What to watch
For ELVN, dilution from the public offering could offset clinical optimism; for AGL, the revenue estimate is slightly down, so the rally may depend on unreported operational metrics not included here.
Background
The article is a multi-name biotech roundup noting 52-week highs on July 16, 2026, attributed to anticipated quarterly reports or conference participation.
Ticker impact
CareDx shares hit a 52-week high after announcing Medicare coverage for AlloSure, AlloMap and AlloSeq transplant molecular tests.
Bullish bias with follow-through risk if conference/earnings details disappoint.
The article ties the spike to a specific Medicare coverage announcement plus revenue growth and 2026 revenue range.
Integra LifeSciences reached a 52-week high as it highlighted product momentum and 2026 revenue expectations alongside recent device approvals.
Moderately bullish, with volatility around any subsequent quarter updates.
The text provides concrete Q1 revenue growth and a full-year 2026 revenue range, but no single new catalyst is dated as same-day.
Agilon Health hit a 52-week high while reiterating 2026 revenue estimate of $5.68B versus $5.93B in 2025.
Range-bound to mildly bullish until the next earnings print clarifies drivers.
The article’s only hard update is the 2026 revenue estimate, which is marginally down, and it does not specify a fresh catalyst beyond anticipated reporting/conference.
Bioventus touched a 52-week high as it reported Q1 revenue up 7% and provided 2026 EPS expectations of $0.75 to $0.79.
Bullish bias, with upside dependent on execution versus the EPS range.
The article includes specific financial metrics (Q1 revenue growth and full-year EPS range) that can drive re-rating.
Enliven Therapeutics rose to a 52-week high after closing a public offering with about $460M gross proceeds and discussing ELVN-001 trial plans.
Mixed-to-neutral near-term, with direction depending on how the market prices dilution versus runway for ENABLE Phase 3.
The offering size is concrete and time-relevant, and the article also references Phase 3 timing, but it lacks details on use of proceeds or pricing.
Market effects
Reimbursement coverage (CDNA) and device/biopharma execution (IART, BVS, ELVN) reinforce that near-term catalysts are driving biotech tape action.
Primarily US-listed biotech sentiment; no explicit cross-region macro linkage provided.
Limited global read-through in the article beyond general biotech risk appetite.
Counterpoint
52-week-high prints may reflect short-term positioning ahead of catalysts; without additional same-day primary disclosures (especially for AGL and IART), momentum can mean-revert.
Key entities
- companyCareDx Inc.
Precision medicine company for transplant patients; Medicare coverage announced for AlloSure/AlloMap/AlloSeq.
- companyIntegra LifeSciences Holdings Corporation
Specialty surgery and tissue reconstruction tools; product approvals and 2026 revenue range discussed.
- companyAgilon Health Inc.
Subscription-based primary care platform for seniors; 2026 revenue estimate reiterated.
- companyBioventus Inc.
Pain management and musculoskeletal medical devices; Q1 revenue growth and 2026 EPS range provided.
- companyEnliven Therapeutics Inc.
Clinical-stage oncology small-molecule inhibitor developer; public offering and ELVN-001 Phase 3 timing mentioned.
